Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sympathetic Overactivity in Essential Hypertension

This study has been withdrawn prior to enrollment.
(No patients could be recruited.)
Information provided by (Responsible Party):
University of Erlangen-Nürnberg Medical School Identifier:
First received: October 9, 2007
Last updated: April 16, 2013
Last verified: April 2013
The primary objective of the study is whether subjects with hypertension and proteinuria display increased sympathetic nerve activity compared to hypertensive subjects without proteinuria and normotensive controls.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Sympathetic Overactivity in Essential Hypertension

Further study details as provided by University of Erlangen-Nürnberg Medical School:

Enrollment: 0
Study Start Date: October 2007
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
hypertensives with proteinuria


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with primary hypertension.

Inclusion Criteria:

  • Normotension or hypertension

Exclusion Criteria:

  • Pregnant and nursing women
  • Myocardial infarction, clinical signs of coronary heart disease
  • Severe depression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00541619

Nephrology and Hypertension, Clinical Research Center
Erlangen, Bavaria, Germany, 91054
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
Principal Investigator: Roland Veelken, MD Principal Investigator
  More Information

Responsible Party: University of Erlangen-Nürnberg Medical School Identifier: NCT00541619     History of Changes
Other Study ID Numbers: RE-No.3210 
Study First Received: October 9, 2007
Last Updated: April 16, 2013
Health Authority: Germany: Ethics Commission

Keywords provided by University of Erlangen-Nürnberg Medical School:
sympathetic activity
early renal damage

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms processed this record on October 25, 2016